A PILOT OPEN-LABEL SINGLE-DOSE TRIAL OF FENOBAM IN ADULTS WITH FRAGILE X SYNDROME Elizabeth Berry-Kravis 1 , David Hessl 2,3 , Sarah Coffey 3,8 , Crystal Hervey 4 , Andrea Schneider 2,3 , Jennifer Yuhas 2 , Julie Hutchison 5 , Michael Snape 5 , Michael Tranfaglia 6 , Danh V. Nguyen 7 , Randi Hagerman 3,8 1 Departments of Pediatrics, Neurological Sciences, Biochemistry, Rush University Medical Center 2 Department of Psychiatry and Behavioral Sciences, University of California Davis 3 M.I.N.D. Institute, University of California Davis Medical Center 4 Department of Pediatrics, Rush University Medical Center 5 Neuropharm LTD 6 FRAXA Research Foundation 7 Department of Public Health Sciences, University of California Davis 8 Department of Pediatrics, University of California Davis Medical Center Address Correspondence to: Elizabeth Berry-Kravis MD PhD Rush University Medical Center 1725 West Harrison Street, Suite 718 Chicago, IL 60612 Key words: fragile X syndrome, fragile X mental retardation protein, fenobam, metabotropic glutamate receptor, prepulse inhibition Running head title: Fenobam in fragile X syndrome Word Count: 3260 JMG Online First, published on January 6, 2009 as 10.1136/jmg.2008.063701 Copyright Article author (or their employer) 2009. Produced by BMJ Publishing Group Ltd under licence. group.bmj.com on February 20, 2016 - Published by http://jmg.bmj.com/ Downloaded from